Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA. Kleiman NS, et al. Among authors: lorenz tj. Circulation. 2000 Feb 22;101(7):751-7. doi: 10.1161/01.cir.101.7.751. Circulation. 2000. PMID: 10683348 Clinical Trial.
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS; ESPRIT investigators. Fernandes LS, et al. Among authors: lorenz tj. J Am Coll Cardiol. 2002 Sep 18;40(6):1085-91. doi: 10.1016/s0735-1097(02)02120-4. J Am Coll Cardiol. 2002. PMID: 12354432 Free article.
Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, Harrington RA. Dyke CM, et al. Among authors: lorenz tj. Ann Thorac Surg. 2000 Sep;70(3):866-71; discussion 871-2. doi: 10.1016/s0003-4975(00)01654-4. Ann Thorac Surg. 2000. PMID: 11016325 Clinical Trial.
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Lopes RD, et al. Among authors: lorenz tj. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019. Am Heart J. 2012. PMID: 22980305 Free PMC article. Clinical Trial.
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: lorenz tj. Am Heart J. 2005 Oct;150(4):643-9. doi: 10.1016/j.ahj.2005.05.021. Am Heart J. 2005. PMID: 16209958
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: lorenz tj. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446. JAMA. 2005. PMID: 16287955 Clinical Trial.
33 results